30/04/2019 - 10:50

PharmAust banks $672,250 R&D tax rebate

30/04/2019 - 10:50

Bookmark

Upgrade your subscription to use this feature.

PharmAust has received a tidy $672,250 R&D tax refund from the Australian Government for its expenditure on the development of its flagship Monepantel anti-cancer drug. This includes work on its successful clinical trials and reformulating a high dose tablet with improved taste. The refund will be used to advance the company’s clinical trial programs in dogs and humans.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options